Glycosylation site-specific antibodies and anti-cancer compounds
US10317409B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Mar 3, 2014 |
| Grant date | Jun 11, 2019 |
| Priority date | — |
| Expiry date | Apr 4, 2035 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2400/02
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
A method of characterizing the protein O-GlcNAcylation site-specificity of an antibody. A method of detecting or quantitating the expression of site-specific O-GlcNAcylated proteins expressed in cells and biological samples. A method of diagnosing cancer in a host based on the cellular expression of site-specific O-GlcNAcylated proteins. A method of screening anti-cancer compounds according to their ability to increase a level O-GlcNAcylation of oncogene or tumor suppressor proteins. Methods of treating cancer in an animal host by administering compounds that increase a level of O-GlcNAcylated c-myc or p53 in cancer cells. A method of distinguishing subclasses of pancreatic cancer according to the sensitivity of pancreatic cancer cells to an imidazole derivative, and a method of personalized pancreatic cancer treatment delivered according to the sensitivity subclasses.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.